Gossamer Bio Inc (GOSS) Shares on the Rise: Short-term Analysis

Gossamer Bio Inc [GOSS] stock is trading at $1.45, up 5.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GOSS shares have gain 14.17% over the last week, with a monthly amount glided 74.91%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 8, January 2024, Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).

From an analyst’s perspective:

Gossamer Bio Inc [NASDAQ: GOSS] stock has seen the most recent analyst activity on July 27, 2023, when UBS downgraded its rating to a Neutral and also revised its price target to $1.25 from $8. Previously, Raymond James downgraded its rating to Mkt Perform on March 07, 2023. On March 01, 2023, Guggenheim initiated with a Neutral rating. SMBC Nikko downgraded its rating to a Neutral but stick to its price target of $3 on December 07, 2022. JP Morgan downgraded its rating to a Underweight. Barclays downgraded its rating to Equal Weight for this stock on December 07, 2022, and downed its price target to $2. In a note dated October 20, 2022, Goldman initiated an Buy rating and provided a target price of $22 on this stock.

Gossamer Bio Inc [GOSS] stock has fluctuated between $0.45 and $1.91 over the past year. Currently, Wall Street analysts expect the stock to reach $3.75 within the next 12 months. Gossamer Bio Inc [NASDAQ: GOSS] shares were valued at $1.45 at the most recent close of the market. An investor can expect a potential return of 158.62% based on the average GOSS price forecast.

Analyzing the GOSS fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is 0.37 and Total Capital is -0.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.06.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3667 points at the first support level, and at 1.2833 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4967, and for the 2nd resistance point, it is at 1.5433.

Gossamer Bio Inc [GOSS] reported earnings per share of -$0.21 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.26/share, meaning a difference of $0.05 and a surprise factor of 19.20%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.45 per share as compared to estimates of -$0.49 per share, a difference of $0.04 representing a surprise of 8.20%.

Ratios To Look Out For

For context, Gossamer Bio Inc’s Current Ratio is 8.07. Also, the Quick Ratio is 8.07, while the Cash Ratio stands at 1.95.

Transactions by insiders

Recent insider trading involved Milligan Sandra, Director, that happened on Nov 15 when 32000.0 shares were purchased. COO/CFO, Giraudo Bryan completed a deal on Nov 13 to buy 0.2 million shares. Meanwhile, Chief Medical Officer Aranda Richard sold 1814.0 shares on Jun 22.

Related Posts